igf-1 lr3 sequence (1 MG) IGF-1 LR3 VIAL - High
Description
A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses
Subcutaneous injection distributes the peptide systemically, meaning it can affect skin throughout the body rather than only where directly applied
Lyon: It is, it's the largest organ system in the body and arguably the most important organ system Dr
1
